Pimecrolimus
- Generic Name
- Pimecrolimus
- Brand Names
- Elidel
- Drug Type
- Small Molecule
- Chemical Formula
- C43H68ClNO11
- CAS Number
- 137071-32-0
- Unique Ingredient Identifier
- 7KYV510875
- Background
Pimecrolimus is an immunomodulating agent that was first marketed by Novartis under the trade name Elidel. It is now promoted in Canada by Galderma since early 2007. It is currently available as a topic cream used in the treatment of atopic dermatitis (eczema).
- Indication
For treatment of mild to moderate atopic dermatitis.
- Associated Conditions
- Vitiligo, Intertriginous psoriasis, Mild Atopic dermatitis, Moderate Atopic dermatitis
- Associated Therapies
- -
1% Topical Pimecrolimus Cream for the Treatment of the Rash Associated With ERBITUX
- First Posted Date
- 2012-09-25
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- West Virginia University
- Target Recruit Count
- 13
- Registration Number
- NCT01692626
- Locations
- 🇺🇸
West Virginia University Hospitals Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States
Pimecrolimus Cream 1% (Elidel®) and Medicated Device Cream (EletoneTM) in the Treatment and Maintenance of Atopic Dermatitis.
- Conditions
- Interventions
- First Posted Date
- 2010-08-09
- Last Posted Date
- 2010-08-09
- Lead Sponsor
- Emer, Jason, M.D.
- Target Recruit Count
- 20
- Registration Number
- NCT01177566
- Locations
- 🇺🇸
Mount Sinai School of Medicine Department of Dermatology Clinical Trials, New York, New York, United States
Effect of Pimecrolimus Cream on Cathelicidin Levels in Subjects With Eczema
- Conditions
- Interventions
- First Posted Date
- 2009-07-27
- Last Posted Date
- 2014-03-10
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 40
- Registration Number
- NCT00946478
- Locations
- 🇺🇸
University of California, San Diego - Dept of Dermatology, La Jolla, California, United States
Open-label Study to Investigate Systemic Exposure in Adult and Pediatric Atopic Dermatitis Patients Treated 8.5 Days With Pimecrolimus Cream 1% Under Occlusion
- First Posted Date
- 2009-06-22
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 20
- Registration Number
- NCT00925730
- Locations
- 🇩🇪
Novartis Investigative Site, Frankfurt am Main, Germany
A Clinical Study in Children and Adolescents With Mild to Moderate Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2007-12-06
- Last Posted Date
- 2015-02-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 80
- Registration Number
- NCT00568412
- Locations
- 🇩🇪
Klinik und Poliklinik fuer Dermatologie, Universtitaetsklinikum, Bonn, Germany
10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus
- First Posted Date
- 2007-12-06
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 8000
- Registration Number
- NCT00568997
- Locations
- 🇺🇸
Registry, Philadelphia, Pennsylvania, United States
Open Label Study of Long Term Treatment of Pediatric Treatment of Atopic Dermatitis With Pimecrolimus Cream 1% Within a Usual Clinical Setting
- Conditions
- First Posted Date
- 2007-08-01
- Last Posted Date
- 2018-04-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT00509990
- Locations
- 🇻🇪
Novartis Investigative Site, Caracas, Venezuela
🇻🇪Novartis Investigative Site, Edo, Carabobo, Venezuela
Assessment of Pruritus Improvement With Pimecrolimus Treatment on the Areas Affected by Mild-to-moderate AD, in Patients 2- to 11- Year-old
- Conditions
- First Posted Date
- 2007-08-01
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 117
- Registration Number
- NCT00510003
- Locations
- 🇪🇸
Novartis Investigative Site, Madrid, Spain
Evaluation of the Antipruritic Effect of Elidel (Pimecrolimus) in Non-atopic Pruritic Disease
- First Posted Date
- 2007-07-27
- Last Posted Date
- 2010-07-07
- Lead Sponsor
- University Hospital Muenster
- Target Recruit Count
- 30
- Registration Number
- NCT00507832
- Locations
- 🇩🇪
Department of Dermtology, University of Münster, Münster, Germany
A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis
- First Posted Date
- 2006-11-23
- Last Posted Date
- 2022-03-14
- Lead Sponsor
- Dermatology Specialists Research
- Target Recruit Count
- 113
- Registration Number
- NCT00403559
- Locations
- 🇺🇸
Dermatology Specialists, Louisville, Kentucky, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.